Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sales Up 1.6%, Vesicare Extends Global Growth: Astellas
May 14, 2012
- DSP’s Sales, Profits Down Due to Strong Yen, 1.6% Decline in Domestic Business
May 14, 2012
- DSP to Reconstruct its Business Strategy Due to Acquisition of BBI and Slow Business in North America
May 14, 2012
- The Growing Presence of Foreign-Affiliates (2)
May 14, 2012
- Struggles in US Operations Lead to 5.3% Fall in Sales, Strategic Products at Home Post 25% Rise: Shionogi
May 11, 2012
- “Figures to Look Forward to in 2013-2014” in Firm US Operations: President Teshirogi of Shionogi
May 11, 2012
- Seikagaku Licenses Domestic Marketing Rights to Kaken Pharmaceutical for Hernia Treatment SI-6603
May 11, 2012
- Executive Officer Terukazu Kato to Become New President: Tsumura
May 11, 2012
- Ono Aims to Decrease Sales Ratio of Long-Listed Drugs to 50% Level within FY2012: President Sagara
May 11, 2012
- Senior Executive Director Mitsutomo Miyashita to Be Appointed as New President: Kyorin
May 11, 2012
- Company Results for March Show Slight Fall in Drug Sales on Impact of Generics: MTPC
May 10, 2012
- Tenelia Planned to “Overwhelm Market with Power” in Alliance with Daiichi Sankyo: MTPC
May 10, 2012
- Japan Blood Products Organization to Begin Operations in October: JRCS, MTPC
May 10, 2012
- Once-Monthly Abilify Significantly Extends Time to Relapse in Adult Schizophrenia Patients: Otsuka
May 10, 2012
- Shionogi’s US Subsidiary Submits NDA for VVA Treatment Ospemifene in the US
May 10, 2012
- Bayer, Santen to Copromote VEGF Trap-Eye Injection
May 10, 2012
- Daiichi Sankyo Ties Up with Coherus BioSciences to Embark on Biosimilars Business
May 9, 2012
- Sanofi-aventis Initiates PIII Trial for Hydroxychloroquine for SLE, CLE
May 9, 2012
- Kyowa Medex Launches Companion Diagnostics of Poteligeo
May 9, 2012
- VIVUS Receives Approval for ED Treatment in the US: MTPC
May 9, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…